Active Vitamin D Analogues
Contraindicated
Textbook
Increased risk of hyperphosphatemia and nephrocalcinosis.
Burosumab is contraindicated with active vitamin D analogues.
Source: G&G 14e · p1065, p1068
Drug reference
burosumab
Monoclonal antibody · Anti-FGF23 antibody
Monoclonal antibodyAnti-FGF23 antibody
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
11 major
incl. contraindicated
PREGNANCY
—
not curated
Top interactionssee all 11 →
- Active Vitamin D AnaloguesContraindicatedTextbookG&G 14e · p1065, p1068
- Oral PhosphateContraindicatedTextbookG&G 14e · p1065, p1068
- CalcifediolSevereDatabaseDDInter
- CalcitriolSevereDatabaseDDInter
Mechanism
A recombinant human monoclonal anti-FGF23 antibody that binds to FGF23 and inhibits its activity, leading to increased phosphate reabsorption and increased serum concentrations of phosphate and calcitriol.
Indications
X-linked hypophosphatemia (XLH)FGF23-related hypophosphatemia in tumor-induced osteomalaciaOsteogenic osteomalacia (to improve metabolic features and potentially bone structure and fracture risk)
Dosing
- Adult
- 0.5 mg/kg every 4 weeks (can be increased to 2 mg/kg every 2 weeks)
- Pediatric
- 1 mg/kg every 4 weeks for X-linked hypophosphatemia.
- Renal adjustment
- Contraindicated in severe kidney impairment or end-stage kidney disease.
Contraindications
- oral phosphate and active vitamin D analogues
- serum phosphorus within or above the normal limits
- severe kidney impairment
- end-stage kidney disease
Side effects
Serious
- nephrocalcinosis
- hyperphosphatemia
Drug interactions
Oral Phosphate
Contraindicated
Textbook
Increased risk of hyperphosphatemia and nephrocalcinosis.
Burosumab is contraindicated with oral phosphate.
Source: G&G 14e · p1065, p1068
Calcifediol
Severe
Database
Clinical effect not specified
Source: DDInter
Calcitriol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Calcium Glycerophosphate
Severe
Database
Clinical effect not specified
Source: DDInter
Calcium Phosphate
Severe
Database
Clinical effect not specified
Source: DDInter
Dihydrotachysterol
Severe
Database
Clinical effect not specified
Source: DDInter
Doxercalciferol
Severe
Database
Clinical effect not specified
Source: DDInter
Monopotassium Phosphate
Severe
Database
Clinical effect not specified
Source: DDInter
Paricalcitol
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Sodium Cellulose Phosphate
Severe
Database
Clinical effect not specified
Source: DDInter
1 additional low-confidence interaction hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Monoclonal antibody drugs
Ask House about burosumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team